Your gift is 100% tax deductible
Español
PDFs by language
Our 24/7 cancer helpline provides information and answers for people dealing with cancer. We can connect you with trained cancer information specialists who will answer questions about a cancer diagnosis and provide guidance and a compassionate ear.
Chat live online
Select the Live Chat button at the bottom of the page
Call us at 1-800-227-2345
Available any time of day or night
Our highly trained specialists are available 24/7 via phone and on weekdays can assist through online chat. We connect patients, caregivers, and family members with essential services and resources at every step of their cancer journey. Ask us how you can get involved and support the fight against cancer. Some of the topics we can assist with include:
For medical questions, we encourage you to review our information with your doctor.
Your gift enables us to support people with cancer and fund research breakthroughs.
The amount must be greater than or equal to $5
Your gift is 100% tax deductible
As researchers have learned more about the changes inside cells that cause cancer, they have developed newer drugs that target these changes. These are often referred to as targeted therapy drugs. These drugs work differently from standard chemotherapy (chemo) drugs. They sometimes work when chemo drugs don’t, and they often have different side effects.
Ibrutinib (Imbruvica) and zanubrutinib (Brukinsa) block a protein called Bruton tyrosine kinase (BTK) inside lymphoma cells, which normally helps the cells grow and survive. Ibrutinib can be used alone or in combination with rituximab to treat WM, while zanubrutinib is typically used by itself. These drugs are taken by mouth as pills, typically once or twice a day.
Common side effects of BTK inhibitors include diarrhea, rash, muscle and bone pain, fatigue, cough, bruising, and low blood cell counts. More serious side effects can include bleeding, serious infections, and heart rhythm problems. Some people taking these drugs develop skin or other cancers, so it’s important to use sun protection when outside while taking one of these drugs.
These drugs stop enzyme complexes (proteasomes) inside cells from breaking down proteins that normally help keep cell division under control.
Bortezomib (Velcade) and carfilzomib (Kyprolis) are sometimes helpful in treating WM. These drugs are given as an infusion into a vein (IV); bortezomib can also be given as an injection under the skin (sub-q).
Although these drugs work slightly differently from most chemo drugs, they can still cause many of the same types of side effects, including low blood counts, nausea, and loss of appetite. They can also damage nerves, causing pain in the feet and legs (peripheral neuropathy). The nerve damage usually gets better after the drug is stopped, but it might not go away completely.
These drugs block a cell protein known as mTOR, which normally helps cells grow and divide into new cells.
Everolimus (Afinitor) is used more often to treat some other types of cancer, but it has also been shown to be useful in treating WM after other treatments have been tried. This drug is taken daily as a pill. Common side effects include fatigue (tiredness), mouth pain, rash, diarrhea, and infections.
Other mTOR inhibitors, such as temsirolimus (Torisel), are now being studied to see if they can help treat WM as well.
Other drugs that target different parts of lymphoma cells are also being studied for use against WM (see What’s New in Waldenstrom Macroglobulinemia Research?).
To learn more about how targeted drugs are used to treat cancer, see Targeted Cancer Therapy.
To learn about some of the side effects listed here and how to manage them, see Managing Cancer-related Side Effects.
The American Cancer Society medical and editorial content team
Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as editors and translators with extensive experience in medical writing.
Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol. 2013;31:88–94.
Buske C, Leblond V, Dimopoulos M, et al. Waldenstrom’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24 Suppl 6:vi155–159.
Dimopoulos MA et al. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia. N Engl J Med. 2018; 378:2399-2410.
Gertz MA. Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management. Am J Hematol. 2017;92:209-217.
Ghobrial IM, Witzig TE, Gertz M, et al. Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom Macroglobulinemia. Am J Hematol. 2014;89:237–242.
National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology: Waldenstrom’s macroglobulinemia/Lymphoplasmacytic lymphoma. V.1.2022. Accessed at www.nccn.org/professionals/physician_gls/pdf/waldenstroms.pdf on September 2, 2021.
Rajkumar SV, Dispenzieri A. Chapter 104: Multiple myeloma and related disorders. In: Niederhuber JE, Armitage JO, Dorshow JH, Kastan MB, Tepper JE, eds. Abeloff’s Clinical Oncology. 5th ed. Philadelphia, Pa. Elsevier: 2014.
Last Revised: September 2, 2021
American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.
Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.
We fund research breakthroughs that save lives. Your year-end gift helps find new treatments for cancer.